| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2009-07-25 00:03:28 UTC |
|---|
| Update Date | 2022-03-07 02:51:27 UTC |
|---|
| HMDB ID | HMDB0012587 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | 15-Epi-lipoxin A4 |
|---|
| Description | 15-Epi-lipoxin A4 is a lipoxin derivative. Lipoxins (LXs) and aspirin-triggered Lipoxin (ATL) are trihydroxytetraene-containing eicosanoids generated from arachidonic acid that are distinct in structure, formation, and function from the many other proinflammatory lipid-derived mediators. These endogenous eicosanoids have now emerged as founding members of the first class of lipid/chemical mediators involved in the resolution of the inflammatory response. Lipoxin A4 (LXA4), ATL, and their metabolic stable analogs elicit cellular responses and regulate leukocyte trafficking in vivo by activating the specific receptor, ALX. Many of the eicosanoids derived from arachidonic acid (AA2), including prostaglandins (PGs) and leukotrienes (LTs), play important roles as local mediators exerting a wide range of actions relevant in immune hypersensitivity and inflammation. However, recent observations indicate that other agents derived from the lipoxygenase (LO) pathways are formed and play a key role in initiating the resolution of acute inflammation. This phenomenon is an active process that is governed by specific lipid mediators and involves a series of well-orchestrated temporal events. Thus, potent locally released mediators serve as checkpoint controllers of inflammation. In addition to the well-appreciated ability of aspirin to inhibit PGs, aspirin also acetylates cyclooxygenase (COX)-2, triggering the formation of a 15-epimeric form of lipoxins, termed aspirin-triggered LXA4 (ATL). These eicosanoids (i.e., LXA4 and ATL) with a unique trihydroxytetraene structure function as 'stop signals' in inflammation and actively participate in dampening host responses to bring the inflammation to a close, namely, resolution. LXA4 and ATL elicit the multicellular responses via a specific G protein-coupled receptor (GPCR) termed ALX that has been identified in human. (PMID: 16968948 , 11478982 ). |
|---|
| Structure | CCCCC[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@H](O)CCCC(O)=O InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18-,19-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 15-Epi-lxa(,4) | HMDB | | 5(S),6(R),15(R)-Trihydroxy-7,9,13-trans-11-cis eicosatetraenoate | HMDB | | 5(S),6(R),15(R)-Trihydroxy-7,9,13-trans-11-cis eicosatetraenoic acid | HMDB | | 5(S),6(R),15(R)-Trihydroxy-7,9,13-trans-11-cis eicosatetraenoic acid anion | HMDB | | 5(S),6(R),15(R)-Trihydroxy-7E,9E,11Z,13E-eicosatetraenoate | HMDB | | 5(S),6(R),15(R)-Trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid | HMDB | | 5(S),6(R),15(R)-Trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid anion | HMDB | | 15-Epi-lxa4 | MeSH, HMDB | | 5,6,15-TriHETE | MeSH, HMDB | | 5,6,15-Trihydroxy-7,9,11,13-eicosatetraenoic acid | MeSH, HMDB | | 5,6,15-Tri-hete | MeSH, HMDB | | LXA4 | MeSH, HMDB | | Lipoxin a4 | MeSH, HMDB | | (5R,6R,7E,9E,11Z,15R)-5,6,15-Trihydroxyicosa-7,9,11,13-tetraenoate | Generator |
|
|---|
| Chemical Formula | C20H32O5 |
|---|
| Average Molecular Weight | 352.4651 |
|---|
| Monoisotopic Molecular Weight | 352.224974134 |
|---|
| IUPAC Name | (5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid |
|---|
| Traditional Name | (5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CCCCC[C@@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@H](O)CCCC(O)=O |
|---|
| InChI Identifier | InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18-,19-/m1/s1 |
|---|
| InChI Key | IXAQOQZEOGMIQS-BZIKWXEGSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as lipoxins. These are eicosanoids with a trihydroxyicosatetraenoic acid skeleton (a c20-fatty acid, with the chain bearing three hydroxyl groups and four double bonds). Lipoxins have four double bonds, which are all conjugated. In some cases a hydroxyl group is substituted by a C=O group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Fatty Acyls |
|---|
| Sub Class | Eicosanoids |
|---|
| Direct Parent | Lipoxins |
|---|
| Alternative Parents | |
|---|
| Substituents | - Lipoxin
- Long-chain fatty acid
- Hydroxy fatty acid
- Fatty acid
- Unsaturated fatty acid
- Secondary alcohol
- Carboxylic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Polyol
- Organic oxide
- Organic oxygen compound
- Hydrocarbon derivative
- Carbonyl group
- Organooxygen compound
- Alcohol
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.49 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 15.4303 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.83 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 48.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2726.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 260.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 168.0 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 186.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 296.4 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 663.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 457.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 109.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1413.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 548.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1395.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 474.4 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 422.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 314.3 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 216.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 15-Epi-lipoxin A4,1TMS,isomer #1 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O)[C@H](O)CCCC(=O)O)O[Si](C)(C)C | 3198.8 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,1TMS,isomer #2 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C)[C@H](O)CCCC(=O)O | 3157.1 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,1TMS,isomer #3 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](CCCC(=O)O)O[Si](C)(C)C | 3154.4 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,1TMS,isomer #4 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@H](O)CCCC(=O)O[Si](C)(C)C | 3112.7 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TMS,isomer #1 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C)[C@H](O)CCCC(=O)O)O[Si](C)(C)C | 3188.5 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TMS,isomer #2 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](CCCC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C | 3182.2 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TMS,isomer #3 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O)[C@H](O)CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3156.1 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TMS,isomer #4 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C)[C@@H](CCCC(=O)O)O[Si](C)(C)C | 3175.2 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TMS,isomer #5 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C)[C@H](O)CCCC(=O)O[Si](C)(C)C | 3109.6 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TMS,isomer #6 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3105.1 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,3TMS,isomer #1 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C)[C@@H](CCCC(=O)O)O[Si](C)(C)C)O[Si](C)(C)C | 3187.2 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,3TMS,isomer #2 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C)[C@H](O)CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3143.5 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,3TMS,isomer #3 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 3130.5 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,3TMS,isomer #4 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C)[C@@H](CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C | 3127.3 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,4TMS,isomer #1 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C)[C@@H](CCCC(=O)O[Si](C)(C)C)O[Si](C)(C)C)O[Si](C)(C)C | 3155.9 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,1TBDMS,isomer #1 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O)[C@H](O)CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3450.6 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,1TBDMS,isomer #2 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)CCCC(=O)O | 3413.6 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,1TBDMS,isomer #3 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3408.0 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,1TBDMS,isomer #4 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@H](O)CCCC(=O)O[Si](C)(C)C(C)(C)C | 3377.5 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TBDMS,isomer #1 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3676.6 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TBDMS,isomer #2 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](CCCC(=O)O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3675.1 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TBDMS,isomer #3 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O)[C@H](O)CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3667.6 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TBDMS,isomer #4 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](CCCC(=O)O)O[Si](C)(C)C(C)(C)C | 3671.2 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TBDMS,isomer #5 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)CCCC(=O)O[Si](C)(C)C(C)(C)C | 3619.3 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,2TBDMS,isomer #6 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3616.4 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,3TBDMS,isomer #1 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](CCCC(=O)O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3954.0 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,3TBDMS,isomer #2 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C(C)(C)C)[C@H](O)CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3914.5 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,3TBDMS,isomer #3 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3913.7 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,3TBDMS,isomer #4 | CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3903.6 | Semi standard non polar | 33892256 | | 15-Epi-lipoxin A4,4TBDMS,isomer #1 | CCCCC[C@H](/C=C/C=C\C=C\C=C\[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](CCCC(=O)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4175.2 | Semi standard non polar | 33892256 |
|
|---|